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A boy with Hodgkin disease contracted breakthrough varicella from his father, who had chickenpox. The boy had
received a single varicella vaccination and was seropositive by enzyme-linked immunosorbent assay before being
diagnosed with breakthrough varicella. Seropositivity after a single varicella vaccination does not guarantee com-
plete protection in an immunocompromised child. (J Pediatr 2013;163:1511-3).From the Divisions of Infectious Diseases/Virology and Hematology/Oncology,
Children’s Hospital, University of Iowa, Iowa City, IA
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his report describes an exception to the guidelines for
managing varicella zoster virus (VZV) infection in
immunocompromised children, as provided in the
2012 Report of the Committee on Infectious Diseases.1 The
guidelines do not recommend any intervention for children
identified as seropositive for varicella antibody when exposed
to varicella. The presence of detectable anti-VZV antibody has
long been considered by infectious disease and hematology-
oncology services as the best indicator of protection against
varicella in their immunocompromised patients. That has
also been our policy at the Children’sHospital at the University
of Iowa for more than 20 years. Here we report a case of break-
through varicella in a cancer patient with a positive screen for
varicella antibody titer and suggest an alternative approach.
Diagnosis of VZV Infection
VZV IgG antibody was detected by enzyme-linked immuno-
sorbent assay (ELISA) with the VIDAS Immunoassay Kit
(bioM_erieux, Durham, North Carolina). For diagnosis of
VZV infection, DNA was extracted from the peripheral white
blood cells and purified using the DNeasy Blood and Tissue
Kit (Qiagen, Valencia, California). VZV DNA was amplified
with primers within ORF62, and the polymerase chain reac-
tion products were subjected to pyrosequencing at the
University of Iowa’s DNA core facility. To distinguish a
wild-type VZV strain from the vaccine strain, single nucleo-
tide polymorphisms within ORF62 were analyzed with refer-
ence to 2 European/North American strains (VZVDumas and
VZV 32), as well as the Japanese parental and vaccine strains
(pOka and vOka), as described previously.2 Varivax (Merck,
West Point, Pennsylvania) is derived from the vOka strain.
Sequences taken from the complete VZV genomes shown in
the Figure have been published previously.3,4
Case Report
A 12 year-old boy with stage IIA Hodgkin disease developed
vesicular lesions on his trunk and left shoulder (Figure,ELISA Enzyme-linked immunosorbent assay
IV Intravenous
VZV Varicella zoster virusday 0). He had been diagnosed with Hodgkin disease 3
months before the current episode. As for all new cancer
patients, we obtained a history, which revealed a single
varicella vaccination at age 1 and confirmed a positive
VZV-IgG antibody titer of >0.90 units (VIDAS Kit;
negative, <0.60; equivocal, 0.60-0.90; positive, >0.90),
before administering chemotherapy or any blood products.
Within 3 months, the patient had completed 4 cycles of
chemotherapy, as well as radiation therapy.
The boy’s father, who is the sole caregiver, had contracted
varicella 9 days before the boy’s rash was evident. The father
had no history of varicella or vaccination. The father was given
a prescription for oral acyclovir after diagnosis. When the fa-
ther’s varicella diagnosis was reported to the child’s physician,
the child was given a single infusion of intravenous (IV)
immunoglobulin (400 mg/kg), owing to the close exposure
to a family member (Figure, A). Nevertheless, the child
presented with varicella 4 days later. Considering that VZV
is transmissible for 2 days before the onset of rash, the
incubation period between father and son was at least 11 days.
The patient was admitted and given IV acyclovir (45mg/kg/
day). His lesions quickly crusted and he was discharged on
oral acyclovir after completing a 5-day course of IV acyclovir.
On day 8, however, he developed new vesicles on his
trunk, and subsequently was readmitted and restarted on IV
acyclovir (Figure, A). He was discharged with a prescription
for oral valacyclovir (1000-mg tablet every 8 hours) for
1 month. His symptoms resolved without a recurrence of
varicella.
A VZV-specific polymerase chain reaction amplification
test performed on a peripheral blood sample obtained on
day 8 was positive for ORF62 sequences resembling those
found in wild-type VZV DNA and negative for those found
in vaccine VZV DNA (Figure, B).conflicts of interest.
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Figure. A, Clinical and virological data from the patient. B,
Molecular diagnosis for VZV infection was performed on day
8, because of the unanticipated recurrence of the vesicular
exanthem after the first hospitalization. Because of the large
number of single nucleotide polymorphisms within VZV
ORF62, a segment of ORF62 was amplified from the VZV-
infected white blood cells, and its sequence was compared
with published sequences of European/North American VZV
strains (Dumas and 32), as well as with the Japanese/Asian
Oka strains. The patient’s VZV strain (1202) was not a vaccine
strain. IVIG, IV immunoglobulin; PO, oral.
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Varicella is the disease caused by primary infection with
VZV.5 Generally, protective immunity after wild-type vari-
cella is life-long, although some exceptions have been pub-
lished.6 Protection after varicella vaccination, especially after
a single varicella vaccination, is not life-long.7 Breakthrough
varicella in otherwise healthy vaccine recipients has become
an increasing problem in the early 21st century in the US,
and universal vaccination with 2 doses of varicella vaccine
was recommended in 2006.1 This recommendation was
based on the presumption that breakthrough varicella likely
occurred in children who had lost serologic evidence of im-
munity many years after their single vaccination, although
primary vaccine failure is another possibility.8 A large sur-
vey of the effectiveness of single-dose vaccination, the Cen-
ters for Disease Control and Prevention cited an important1512analysis that controlled for the effects of age of vaccination,
age of breakthrough varicella, and year of infection and
found a 2.6-fold greater risk for moderate to severe break-
through varicella in children who had received a single vari-
cella vaccine >5 years earlier compared with children who
had been vaccinated <5 years before exposure to wild-type
varicella.9 Our case fits into that risk group, and illustrates
the need for a second varicella vaccination, especially as a
catch-up vaccination in older children and adolescents to
prevent breakthrough varicella.1 Finally, there may have
been a predisposition to breakthrough varicella in our
case because of an unrecognized decline in cell-mediated
immunity secondary to the anticancer therapies5; however,
we did not evaluate VZV cell-mediated immunity in this
patient.
A previous report described 9 children with leukemia who
contracted a second bout of wild-type varicella despite a pos-
itive VZV ELISA titer (using the Diamedix VZV Test Kit;
Miami, Florida) at the time of cancer diagnosis.10 Of note,
most of these second cases also had household exposures to
wild-type varicella. The authors proposed the wider use of
prophylactic acyclovir.
In summary, our case report suggests that immunocom-
promised children with a multiday household exposure to
wild-type varicella may need prophylaxis with either a Vari-
ZIG injection (Cangene, Winnipeg, Manitoba, Canada) or
oral acyclovir if they have had only a single varicella vaccina-
tion, regardless of the presence or absence of detectable anti-
body by the widely used commercial VZV antibody kits. The
VZV fluorescent antibody to membrane antigen test may
provide more predictable protective titers than ELISA, but
is currently available in only a few research laboratories.8 n
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